#United States #New York #Class Action #Securities Fraud #Capricor Therapeutics

Capricor Therapeutics Faces Legal Challenges

Capricor Therapeutics, Inc. has recently come under scrutiny following the announcement of a class action lawsuit filed against it and several senior executives. The lawsuit stems from serious allegations of securities fraud, linked to misstatements regarding Deramiocel, the company's lead product, and the clinical data supporting its Biologics License Application (BLA).

On July 27, 2026, the company's stock experienced a staggering drop of 64.5%, plummeting from $19.70 to just $7.00 per share. The reasons behind this dramatic decline were made evident when the FDA released briefing documents that raised serious concerns about the integrity of the clinical trial data for Deramiocel. Investors now have until September 28, 2026, to join the lawsuit, officially known as Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385, filed at the U.S. District Court for the Southern District of California.

Allegations of Securities Fraud

The lawsuit alleges that Capricor made false statements regarding the clinical efficacy of Deramiocel while failing to disclose critical modifications made to the pre-specified statistical analysis plan essential to the evaluation of its effectiveness for treating Duchenne muscular dystrophy (DMD). This lack of transparency raises alarm regarding the company’s compliance with federal securities laws.

The formal complaint highlights that Capricor submitted its BLA to the FDA in late 2024; however, by July 2025, the FDA issued a Complete Response Letter, indicating that the evidence presented did not meet the established requirements for demonstrating the drug’s effectiveness. In late July 2026, the FDA's concerns about the study's statistical methodology and other elements led to further investor panic.

The Fallout for Capricor Investors

Investors have been encouraged to evaluate their options regarding the potential lawsuit. Bleichmar Fonti & Auld LLP, the leading firm behind this case, is offering further details on how affected investors can participate. Under securities laws, shareholders are seeking recompenses owing to misrepresentations that have adversely impacted their investments.

While the class action remains under judicial consideration, defendants include both the company and notable executives, whose actions and decisions led to this unfortunate scenario. The impact of woven communications on the public perception of Capricor has caused significant market repercussions, highlighting the critical necessity for corporate governance and financial disclosures.

Hope for Recovering Losses

Investors should act quickly, as the September 28 deadline approaches. All potential representation will be on a contingency basis, ensuring that shareholders are not burdened with legal fees unless the case yields positive results. The firm intends to seek judicial approval for any costs incurred during the legal process on behalf of the class.

Final Thoughts

This developing case serves as a critical reminder of the volatile nature of investing in biotechnology firms, especially those dealing with high-stakes therapies in the regulatory pipeline. As the situation unfolds, stakeholders in Capricor Therapeutics must stay informed and proactive about their rights and options. For more information, shareholders are encouraged to explore the law firm's resources here.

Take Action

If you are among those impacted by the declines in Capricor shares, do not hesitate to reach out for legal guidance and explore your potential claims.

About Bleichmar Fonti & Auld LLP

Bleichmar Fonti & Auld LLP is a well-respected law firm known for its dedication to representing investors in securities litigation. They recently received high accolades for client satisfaction and have a history of significant recoveries in similar cases, including multi-million dollar settlements in corporate fraud litigation.